More Vaccines Restructuring As Daiichi's Oncology Pivot Gains Momentum

 
• By Ian Haydock

Daiichi Sankyo makes further vaccine business restructuring moves as it emphasizes oncology amid global generic challenges to its former big seller olmesartan.

production line
Daiichi Rejigs Vaccine Ops As Oncology Builds • Source: Shutterstock

More from Japan

More from Focus On Asia